GlassScriptPhysician profile
Teron Verma
NPI 1356704225
$2,073.17
in general payments reported to CMS, 2019-2025
23 companies · $698 in 2025
The $698 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $11.62 · 2021: $86.09 · 2022: $303 · 2023: $431 · 2024: $290 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Education: $76.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.51 |
| Education | $76.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.67 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $372.94 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.36 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $143.01 | 2025 | Auvelity |
| Corium, LLC | $113.15 | 2022-2025 | Azstarys |
| Alkermes, INC. | $106.81 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $105.42 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $89.44 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $61.30 | 2019-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.53 | 2023-2025 | Trintellix |
| Shire North American Group INC | $54.39 | 2019 | |
| Neurocrine Biosciences, INC. | $47.93 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $47.05 | 2025 | Fanapt |
| Allergan, INC. | $46.27 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.05 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $33.67 | 2025 | Jornay Pm |
| Lundbeck LLC | $30.18 | 2025 | Rexulti |
| Tris Pharma INC | $28.69 | 2019 | |
| Neuronetics, INC. | $17.76 | 2025 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $14.89 | 2025 | Qelbree |
| Noven Pharmaceuticals, INC. | $14.55 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $14.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teron Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.